Britannia Life Sciences Inc.
BLAB
CNSX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -13.40% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -13.40% | |||
| Cost of Revenue | -- | 10.63% | |||
| Gross Profit | -- | -25.07% | |||
| SG&A Expenses | -- | 54.14% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -- | 34.10% | |||
| Operating Income | -- | -129.32% | |||
| Income Before Tax | -- | 96.48% | |||
| Income Tax Expenses | -- | -59.63% | |||
| Earnings from Continuing Operations | -- | 91.47% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | 63.43% | |||
| Net Income | -- | 88.83% | |||
| EBIT | -- | -129.32% | |||
| EBITDA | -- | -123.65% | |||
| EPS Basic | 0.00% | 88.89% | |||
| Normalized Basic EPS | -- | 76.47% | |||
| EPS Diluted | 0.00% | 88.89% | |||
| Normalized Diluted EPS | -- | 76.47% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||